A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
125actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-25 | actual | When the study began enrolling |
| Primary completion | 2025-09-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-26 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: Bimagrumab — also filed as LY3985863, BYM338, VER201
- Drug: Tirzepatide — also filed as LY3298176
- Drug: Bimagrumab + Tirzepatide Coformulation — also filed as LY900042
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material
measured Predose through Week 13
PK: Cmax of Bimagrumab Reference Material
measured Predose through Week 13
PK: Cmax of Bimagrumab Coadministered with Tirzepatide
measured Predose through Week 13
PK: Cmax of Tirzepatide Coadministered with Bimagrumab
measured Predose through Week 16
PK: Cmax of Bimagrumab Coformulated with Tirzepatide
measured Predose through Week 16
PK: Cmax of Tirzepatide Coformulated with Bimagrumab
measured Predose through Week 16
PK: Area Under the Curve from Zero to Infinity AUC (AUC(0-∞)) of Bimagrumab Test Material
measured Predose through Week 13
PK: AUC(0-∞) of Bimagrumab Reference Material
measured Predose through Week 13
PK: AUC(0-∞) of Bimagrumab Coadministered with Tirzepatide
measured Predose through Week 13
PK: AUC(0-∞) of Tirzepatide Coadministered with Bimagrumab
measured Predose through Week 16
PK: AUC(0-∞) of Bimagrumab Coformulated with Tirzepatide
measured Predose through Week 16
PK: AUC(0-∞) of Tirzepatide Coformulated with Bimagrumab
measured Predose through Week 16
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed